UNITED GUARDIAN INC - Quarter Report: 2013 June (Form 10-Q)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
|
[X]
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2013
|
[ ]
|
TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _________ to _________
Commission File Number: 1-10526
| UNITED-GUARDIAN, INC. |
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 11-1719724 | |
| (State or Other Jurisdiction of | (I.R.S. Employer Identification No.) | |
| Incorporation or Organization) |
| 230 Marcus Boulevard, Hauppauge, New York 11788 | ||
| (Address of Principal Executive Offices) |
|
(631) 273-0900
|
||
|
(Registrant’s Telephone Number)
|
| N/A |
|
(Former name, former address and former fiscal year, if changed since last report)
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]
Cover Page 1 of 2
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | [ ] | |
| Non-accelerated filer | [ ] (Do not check if a smaller reporting company) | |
| Accelerated filer | [ ] | |
| Smaller reporting company | [X] |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)
Yes [ ] No [X]
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:
4,596,439 shares of common stock, par value $.10 per share
(as of August 1, 2013)
Cover Page 2 of 2
UNITED-GUARDIAN, INC.
INDEX TO FINANCIAL STATEMENTS
Page 1 of 18
|
ITEM 1.
|
|
THREE MONTHS ENDED
JUNE 30,
|
SIX MONTHS ENDED
JUNE 30,
|
|||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Net sales
|
$ | 3,628,571 | $ | 3,735,100 | $ | 7,580,732 | $ | 7,623,792 | ||||||||
|
Costs and expenses:
|
||||||||||||||||
|
Cost of sales
|
1,363,295 | 1,465,119 | 2,774,451 | 3,004,959 | ||||||||||||
|
Operating expenses
|
635,891 | 548,254 | 1,197,459 | 1,151,117 | ||||||||||||
|
Total costs and expenses
|
1,999,186 | 2,013,373 | 3,971,910 | 4,156,076 | ||||||||||||
|
Income from operations
|
1,629,385 | 1,721,727 | 3,608,822 | 3,467,716 | ||||||||||||
|
Other income:
|
||||||||||||||||
|
Investment income
|
64,925 | 41,757 | 119,107 | 111,348 | ||||||||||||
|
Gain on sale of assets
|
--- | --- | --- | 2,750 | ||||||||||||
|
Income from damage settlement
|
292,830 | --- | 585,660 | --- | ||||||||||||
|
Total other income
|
357,755 | 41,757 | 704,767 | 114,098 | ||||||||||||
|
Income before income taxes
|
1,987,140 | 1,763,484 | 4,313,589 | 3,581,814 | ||||||||||||
|
Provision for income taxes
|
644,600 | 570,400 | 1,406,400 | 1,160,100 | ||||||||||||
|
Net Income
|
$ | 1,342,540 | $ | 1,193,084 | $ | 2,907,189 | $ | 2,421,714 | ||||||||
|
Earnings per common share (Basic and Diluted)
|
$ | 0.29 | $ | 0.26 | $ | 0.63 | $ | 0.53 | ||||||||
|
Weighted average shares – basic and diluted
|
4,596,439 | 4,596,439 | 4,596,439 | 4,596,439 | ||||||||||||
See notes to condensed financial statements
|
THREE MONTHS ENDED
JUNE 30,
|
SIX MONTHS ENDED
JUNE 30,
|
|||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Net income
|
$ | 1,342,540 | $ | 1,193,084 | $ | 2,907,189 | $ | 2,421,714 | ||||||||
|
Other comprehensive (loss) income:
|
||||||||||||||||
|
Unrealized (loss) gain on marketable securities during period
|
(211,917 | ) | 69,362 | (186,205 | ) | 164,533 | ||||||||||
|
Income tax benefit (expense) related to other comprehensive income
|
74,056 | (24,041 | ) | 65,024 | (57,028 | ) | ||||||||||
|
Other comprehensive (loss) income, net of tax
|
(137,861 | ) | 45,321 | ( 121,181 | ) | 107,505 | ||||||||||
|
Comprehensive income
|
$ | 1,204,679 | $ | 1,238,405 | $ | 2,786,008 | $ | 2,529,219 | ||||||||
See notes to condensed financial statements
Page 3 of 18
UNITED-GUARDIAN, INC.
|
ASSETS
|
JUNE 30,
2013
|
DECEMBER 31,
2012
|
||||||
|
(UNAUDITED)
|
(AUDITED)
|
|||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 2,103,554 | $ | 1,748,382 | ||||
|
Marketable securities
|
8,579,721 | 7,743,946 | ||||||
|
Accounts receivable, net of allowance for doubtful accounts of $29,000 at June 30, 2013 and December 31, 2012
|
1,444,342 | 1,017,627 | ||||||
|
Receivable in connection with damage settlement
|
97,610 | 518,050 | ||||||
|
Inventories (net)
|
1,020,934 | 1,242,750 | ||||||
|
Prepaid expenses and other current assets
|
193,659 | 132,458 | ||||||
|
Prepaid income taxes
|
--- | 3,602 | ||||||
|
Deferred income taxes
|
216,588 | 216,588 | ||||||
|
Total current assets
|
13,656,408 | 12,623,403 | ||||||
|
Property, plant and equipment:
|
||||||||
|
Land
|
69,000 | 69,000 | ||||||
|
Factory equipment and fixtures
|
3,928,753 | 3,842,927 | ||||||
|
Building and improvements
|
2,730,413 | 2,725,993 | ||||||
|
Waste disposal plant
|
133,532 | 133,532 | ||||||
|
Total property, plant and equipment
|
6,861,698 | 6,771,452 | ||||||
|
Less: Accumulated depreciation
|
5,629,010 | 5,535,589 | ||||||
|
Total property, plant and equipment, net
|
1,232,688 | 1,235,863 | ||||||
|
TOTAL ASSETS
|
$ | 14,889,096 | $ | 13,859,266 | ||||
See Notes to Condensed Financial Statements
Page 4 of 18
UNITED-GUARDIAN, INC.
BALANCE SHEETS
(continued)
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
JUNE 30,
2013 |
DECEMBER 31,
2012 |
|||||||
|
Current liabilities:
|
(UNAUDITED)
|
(AUDITED)
|
||||||
|
Accounts payable
|
$ | 162,494 | $ | 151,385 | ||||
|
Accrued expenses
|
1,036,860 | 676,123 | ||||||
|
Income taxes payable
|
97,324 | --- | ||||||
|
Total current liabilities
|
1,296,678 | 827,508 | ||||||
|
Deferred income taxes
|
128,716 | 193,740 | ||||||
|
Commitment (Note 13)
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Common stock $.10 par value, authorized, 10,000,000 shares; 4,596,439 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively.
|
459,644 | 459,644 | ||||||
|
Accumulated other comprehensive income
|
57,799 | 178,979 | ||||||
|
Retained earnings
|
12,946,259 | 12,199,395 | ||||||
|
Total stockholders’ equity
|
13,463,702 | 12,838,018 | ||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$ | 14,889,096 | $ | 13,859,266 | ||||
See Notes to Condensed Financial Statements
|
SIX MONTHS ENDED
June 30, |
||||||||
|
2013
|
2012
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net income
|
$ | 2,907,189 | $ | 2,421,714 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
|
Depreciation and amortization
|
93,421 | 122,836 | ||||||
|
Realized (gain) loss on sale of investments
|
(13,439 | ) | 30,975 | |||||
|
Realized (gain) on sale of assets
|
--- | (2,750 | ) | |||||
|
(Decrease) increase in cash resulting from changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(426,715 | ) | (359,219 | ) | ||||
|
Receivable from damage settlement
|
420,440 | --- | ||||||
|
Inventories
|
221,816 | 339,609 | ||||||
|
Prepaid expenses and other current and non-current assets
|
(61,201 | ) | (4,692 | ) | ||||
|
Prepaid taxes
|
3,602 | 78,613 | ||||||
|
Accounts payable
|
11,109 | (274,130 | ) | |||||
|
Accrued expenses and taxes payable
|
458,061 | 434,789 | ||||||
|
Net cash provided by operating activities
|
3,614,283 | 2,787,745 | ||||||
|
Cash flows from investing activities:
|
||||||||
|
Acquisition of property, plant and equipment
|
(90,246 | ) | (70,634 | ) | ||||
|
Proceeds from sale of assets
|
--- | 2,750 | ||||||
|
Proceeds from sale of marketable securities
|
1,719,983 | 1,615,600 | ||||||
|
Purchases of marketable securities
|
(2,728,522 | ) | (1,659,817 | ) | ||||
|
Net cash used in investing activities
|
(1,098,785 | ) | (112,101 | ) | ||||
|
Cash flows from financing activities:
|
||||||||
|
Dividends paid
|
(2,160,326 | ) | (1,930,504 | ) | ||||
|
Net cash used in financing activities
|
(2,160,326 | ) | (1,930,504 | ) | ||||
|
Net increase in cash and cash equivalents
|
355,172 | 745,140 | ||||||
|
Cash and cash equivalents at beginning of period
|
1,748,382 | 1,090,974 | ||||||
|
Cash and cash equivalents at end of period
|
$ | 2,103,554 | $ | 1,836,114 | ||||
See Notes to Condensed Financial Statements
Page 6 of 18
UNITED-GUARDIAN, INC.
(UNAUDITED)
|
1.
|
Nature of Business
|
United-Guardian, Inc. (the “Company”) is a Delaware corporation that, through its Guardian Laboratories Division, conducts research, product development, manufacturing and marketing of cosmetic ingredients and other personal care products, pharmaceuticals, medical and health care products and proprietary specialty industrial products.
|
2.
|
Basis of Presentation
|
Interim financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation SX. In the opinion of management, all adjustments, consisting solely of normal recurring accruals, considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and six months ended June 30, 2013 (also referred to as the "second quarter of 2013" and the "first half of 2013", respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2013. The interim unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2012.
|
3.
|
Stock-Based Compensation
|
The Company maintains a stock-based compensation plan for its employees and directors, which is more fully described in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company recognizes the fair value of all share-based payments to employees, including grants of employee stock options, as a compensation expense in the financial statement. As of June 30, 2013, the Company had no share-based awards outstanding and exercisable and did not grant any options during the second quarter of 2013 or for the first half of 2013.
|
4.
|
Recent Accounting Pronouncements
|
In February 2013, FASB issued ASU 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income." This update requires the Company to report amounts being reclassified out of accumulated other comprehensive income by component. It also requires the Company to report either on the face of the financial statements or in the notes any significant amounts reclassified out of accumulated other comprehensive income, by the respective line items of net income, but only if the item reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For those amounts not required to be reclassified directly to net income in their entirety, the Company is required to cross-reference other disclosures that provide further details about the amounts. The amendments are effective for reporting periods beginning after December 15, 2012. The Company adopted this amendment effective January 1, 2013. The adoption of this amendment did not have a material impact on the Company's results of operations.
Page 7 of 18
|
5.
|
Investments
|
The fair values of the Company’s marketable securities are determined in accordance with GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by GAAP, which prioritizes the inputs used in measuring fair value, as follows:
|
•
|
Level 1 -
|
inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
|
•
|
Level 2 -
|
inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
|
|
•
|
Level 3 -
|
inputs to the valuation methodology are unobservable and significant to the fair value measurement.
|
The following available-for-sale securities, which comprise all the Company’s marketable securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs, which are quoted prices (unadjusted) for identical assets in active markets:
|
June 30, 2013
|
Cost
|
Fair Value
|
Unrealized
Gain/(Loss) |
|||||||||
|
Available for sale:
|
||||||||||||
|
Corporate bonds (matures within 1 year)
|
$ | 203,920 | $ | 201,903 | $ | (2,017 | ) | |||||
|
Fixed income mutual funds
|
8,014,670 | 8,049,006 | 34,336 | |||||||||
|
Equity and other mutual funds
|
273,416 | 328,812 | 55,396 | |||||||||
| $ | 8,492,006 | $ | 8,579,721 | $ | 87,715 | |||||||
|
December 31, 2012
|
Cost
|
Fair Value
|
Unrealized
Gain/(Loss)
|
|||||||||
|
Available for Sale:
|
||||||||||||
|
Corporate bonds (maturities of 1-5 years)
|
$ | 203,920 | $ | 203,357 | $ | (563 | ) | |||||
|
Fixed income mutual funds
|
6,991,181 | 7,242,998 | 251,817 | |||||||||
|
Equity and other mutual funds
|
274,926 | 297,591 | 22,665 | |||||||||
| $ | 7,470,027 | $ | 7,743,946 | $ | 273,919 | |||||||
Proceeds from the sale and redemption of marketable securities amounted to $1,719,983 for the first half of 2013, which included realized gains of $13,439. Proceeds from the sale and redemption of marketable securities amounted to $1,615,600 for the first half of 2012, which included realized losses of $30,975.
Investment income consisted principally of interest income from bonds and money market funds and dividend income from bond funds and mutual funds.
Page 8 of 18
Marketable securities include investments in equity and fixed income mutual funds, government securities and corporate bonds which are classified as “available-for-sale” securities and are reported at their fair values. Unrealized gains and losses on “available-for-sale” securities are reported as accumulated other comprehensive income (loss) in stockholders’ equity, net of the related tax effects. Investment income is recognized when earned. Realized gains and loses on sales of investments are determined on a specific identification basis.
|
6.
|
Inventories
|
|
June 30,
2013 |
December 31,
2012 |
|||||||
|
Inventories consist of the following:
|
||||||||
|
Raw materials and work in process
|
$ | 519,478 | $ | 481,544 | ||||
|
Finished products
|
501,456 | 761,206 | ||||||
| $ | 1,020,934 | $ | 1,242,750 | |||||
Inventories are valued at the lower of cost or current market value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out ("FIFO") method. Finished product inventories at June 30, 2013 and December 31, 2012 are stated net of a reserve of $20,000 for slow-moving or obsolete inventory.
|
7.
|
Supplemental Financial Statement Information
|
For purposes of the Statements of Cash Flows, the Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents.
Cash payments for taxes were $1,305,474 and $1,016,745 for the first half of 2013 and 2012, respectively. No payments were made for interest during these periods.
The Company paid $2,160,326 ($0.47 per share) and $1,930,504 ($0.42 per share) in dividends for the first half of 2013 and 2012, respectively.
Research and development expenses amounted to $298,923 and $290,390 for the first half of 2013 and 2012, respectively, and $150,624 and $144,048 for the second quarters of 2013 and 2012, respectively. These costs are included in operating expenses.
|
8.
|
Income Taxes
|
The Company’s tax provision is based on its estimated annual effective rate. The Company continues to fully recognize its tax benefits, which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized. As of June 30, 2013 and December 31, 2012, the Company did not have any unrecognized tax benefits.
The Company files consolidated Federal income tax returns in the U.S. with its inactive subsidiary, and separate income tax returns in New York State. The Company is subject to examination by the Internal Revenue Service and by the State of New York for years 2009 through 2012.
The Company's policy is to recognize interest and penalties in interest expense.
Page 9 of 18
|
9.
|
Comprehensive Income
|
Accumulated other comprehensive income comprises unrealized gains and losses on marketable securities net of the related tax effect.
|
Changes in Accumulated Other Comprehensive Income
|
June 30, 2013
|
June 30, 2012
|
||||||
|
Beginning balance – net of tax
|
$ | 178,979 | $ | 34,612 | ||||
|
Unrealized (loss)/gain on marketable securities before reclassifications - net of tax
|
(134,619 | ) | 138,480 | |||||
|
Realized gain/(loss) on sale of securities reclassified from accumulated other comprehensive income
|
13,439 | (30,975 | ) | |||||
|
Ending balance - net of tax
|
$ | 57,799 | $ | 142,117 | ||||
|
10.
|
Income from Damage Settlement
|
In May 2012 the Company's supplier of RENACIDIN® IRRIGATION (“RENACIDIN”) curtailed production due to manufacturing issues. As a result of that curtailment, the Company and its supplier entered into a settlement agreement whereby the supplier agreed to pay the Company $518,050 for profit the Company lost during 2012 as a result of the curtailment, and an additional $97,610 a month beginning January 1, 2013 for each month that the curtailment continues. The payments are to continue until either the supply contract ends in January 2014 or until production resumes, whichever occurs first. The income from the damage settlement in the second quarter of 2013 was $292,830, and for the first half of 2013 was $585,660.
|
11.
|
Defined Contribution Plan
|
The Company sponsors a 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions after one year of employment. For the three and six months ended June 30, 2013 and 2012, the Company had accrued for contributions of $43,750 and $87,500, respectively, to the DC Plan. For the first half of 2013 and 2012, the Company did not make any discretionary contributions to the DC Plan.
|
12.
|
Related-Party Transactions
|
During the first half of 2013 and 2012, the Company paid to Bonamassa, Maietta and Cartelli, LLP $2,000 and $6,000 in each period, for accounting and tax services. Lawrence Maietta, a partner in Bonamassa, Maietta and Cartelli, LLP, is a director of the Company.
Page 10 of 18
|
13.
|
Capital Expenditure Commitment
|
As part of the Company’s ongoing project to change to a new contract manufacturer for RENACIDIN, and to change the packaging of RENACIDIN from glass to plastic, the Company has contracted for the development and production of a mold and other related production equipment that will enable the Company’s new supplier to produce the new plastic bottles. The equipment will be owned by the Company, and can be used at other manufacturing facilities if necessary. The cost of manufacturing the mold and related equipment is estimated to be approximately $167,000, of which the Company has already paid $57,490, which covers the work performed by the manufacturer of the mold as of June 30, 2013. The balance is expected to be paid by the end of the third quarter of 2013, when the remainder of the work on the mold is expected to be completed.
|
14.
|
Other Information
|
| Accrued Expenses | ||||||||
| June 30,
2013
|
December 31,
2012
|
|||||||
|
Accrued bonuses
|
$ | 509,615 | $ | 229,000 | ||||
|
Accrued 401K plan contributions
|
87,500 | --- | ||||||
|
Accrued distribution fees
|
174,476 | 196,617 | ||||||
|
Payroll and related expenses
|
162,193 | 72,306 | ||||||
|
Accrued annual report
|
33,589 | 66,000 | ||||||
|
Accrued audit fee
|
43,769 | 68,467 | ||||||
|
Other
|
25,718 | 43,733 | ||||||
| $ | 1,036,860 | $ | 676,123 | |||||
FORWARD-LOOKING STATEMENTS
Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-looking statements may be identified by the use of such words as “believes”, “may”, “will”, “should”, “intends”, “plans”, “estimates”, “anticipates”, or other similar expressions.
Page 11 of 18
Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; changes in intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices.
Accordingly, results actually achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.
OVERVIEW
The Company is a Delaware corporation that conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. All of the products that the Company manufactures, with the exception of RENACIDIN, are produced at its facility in Hauppauge, New York, and are marketed through marketing partners, distributors, wholesalers, direct advertising, mailings, and trade exhibitions. Its most important personal care product line is its LUBRAJEL® line of water-based moisturizing and lubricating gels. It also sells two pharmaceutical products for urological uses. Those products are sold primarily through the major drug wholesalers, which in turn sell the products to pharmacies, hospitals, nursing homes and other long-term care facilities, and to government agencies, primarily the United States Department of Veterans Affairs.
The Company’s pharmaceutical products are distributed primarily in the United States. Its personal care products are marketed worldwide by five marketing partners, of which Ashland Specialty Ingredients ("ASI") purchases the largest volume of products from the Company. Approximately one-half of the Company's products are sold, either directly or through the Company’s marketing partners, to end users located outside of the United States. The Company's non-pharmaceutical medical products (referred to hereinafter as "medical products"), such as its catheter lubricants, as well as its specialty industrial products, are sold directly by the Company to the end users or to contract manufacturers utilized by the end users, although they are available for sale on a non-exclusive basis by its marketing partners, as well.
While the Company does have competition in the marketplace for some of its products, many of its products are either unique in their field or have some unique characteristics, and therefore are not in direct competition with the products of other pharmaceutical, specialty chemical, or health care companies. Many of the Company’s products are manufactured using patented or proprietary processes. The Company’s research and development department is actively working on the development of new products to expand the Company's line of personal care and performance products.
The Company recognizes revenue when products are shipped, title and risk of loss pass to the customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.
Page 12 of 18
The Company has been issued many patents and trademarks and intends, whenever possible, to make efforts to obtain patents in connection with its product development program.
CRITICAL ACCOUNTING POLICIES
As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2012, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.
The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2012, and a comparison of the results of operations for the second quarter of 2013 and 2012, and the first half of 2013 and 2012. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis or Plan of Operation" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
RESULTS OF OPERATIONS
|
|
Sales
|
Net sales for the second quarter of 2013 decreased by $106,529 (2.9%) compared with the comparable period in 2012. Net sales for the first half of 2013 decreased by $43,060 (0.6%) as compared with the corresponding period in 2012. The changes in net sales for the second quarter of 2013 and the first half of 2013 were attributable to changes in sales of the following product lines:
|
(a)
|
Personal care products: For the second quarter of 2013 the Company’s sales of personal care products increased by $231,363 (9.5%) when compared with the second quarter of 2012, and for the first half of 2013 the Company’s sales of personal care products increased by $599,127 (11.9%) when compared with the comparable period in 2012. The increase in sales in the second quarter of 2013 and for the first six months of 2013 were primarily due to an increase in sales of the Company's extensive line of personal care products to ASI, the Company's largest marketing partner. Sales to ASI increased by $225,908 (11.6%) and $531,703 (12.7%) for the three- and six-month periods, respectively, ended June 30, 2013, compared with the corresponding periods in 2012. Other factors contributing to the increase in sales were (a) customer replenishment of products with low inventory levels, and (b) the timing of orders.
|
Page 13 of 18
|
(b)
|
Pharmaceuticals: For the second quarter of 2013 the Company's sales of pharmaceutical products decreased by $431,043 (79.7%) when compared with the second quarter of 2012, and for the first half of 2013 the Company's sales of pharmaceutical products decreased by $1,001,741 (82.1%) when compared with the comparable period of 2012. The decrease was due to there being no sales of RENACIDIN in the first half of 2013 when compared with the same period in 2012. The inability of the Company to replenish its RENACIDIN inventory was the result of production issues experienced by the Company's sole supplier for that product. The Company's RENACIDIN inventory was completely depleted on August 1, 2012, and there have been no RENACIDIN sales since that time. The Company's supplier is paying the Company $97,610 for each month that the product is not available, which the Company believes covers most of its lost profits each month. This will continue until either production resumes or the contract with the supplier ends on January 20, 2014, whichever comes first.
The Company is currently working with a new supplier that will manufacture the product in a new single-dose unit. The Company is hopeful that the U.S. Food and Drug Administration will approve the new supplier by the end of 2014. Until then, the Company is continuing to work closely with the current supplier to resume production as soon as possible. The current timetable calls for production to resume in September 2013. If that takes place, the Company would be able to resume RENACIDIN sales in October 2013. The Company intends to bring in sufficient inventory to last until the new supplier is approved and begins supplying the new single-dose unit.
|
|
(c)
|
Medical (non-pharmaceutical) products: Sales of the Company’s medical products increased by $102,290 (13.7%) for the second quarter of 2013, and increased by $313,306 (22.3%) for the first half of 2013 compared with the comparable periods in 2012. These changes were primarily attributable to the ordering patterns of the Company's customers for these products.
|
|
(d)
|
Industrial and other products: Sales of the Company's industrial products, as well as other miscellaneous products, decreased by $35,705 (52.6%) and $14,450 (16.1%) for the three and six months, respectively, ended June 30, 2013, when compared with the corresponding periods ended June 30, 2012.
|
In addition to the above changes in sales, net sales allowances decreased by $26,566 and $60,698 for the three and six months, respectively, ended June 30, 2013, when compared with the corresponding periods in 2012. The decreases were primarily due to a decrease in chargebacks paid to the U.S. Department of Veterans Affairs, a reduction in pharmaceutical sales rebates to state Medicaid agencies, and lower distribution fees due to the lack of RENACIDIN sales.
Cost of Sales
For the second quarter of 2013, cost of sales as a percentage of sales decreased to 37.6%, down from 39.2% in the second quarter of 2012. Cost of sales as a percentage of sales decreased to 36.6% for the first half of 2013, down from 39.4% for the comparable period in 2012. The decreases were primarily the result of the change in the company's product mix due to the absence of RENACIDIN sales in 2013, and a proportionate increase in sales of the Company's higher-margin LUBRAJEL products.
Page 14 of 18
Operating Expenses
Operating expenses consist of selling, general and administrative expenses. Operating expenses increased by $87,637 (16.0%) for the second quarter of 2013 compared with the comparable quarter in 2012, and increased by $46,342 (4.0%) for the first half of 2013 compared with the first half of 2012. The increases in operating expenses for the second quarter and first half of 2013 were primarily attributable to increases in payroll and payroll related expenses and automobile expenses.
Other Income
Other income increased by $315,998 for the second quarter of 2013 compared with the comparable quarter of 2012, and increased by $590,669 for the first half of 2013 compared with the first half of 2012. The increases for the second quarter and first half of 2013 were mainly attributable to the $292,830 and $585,660, respectively, that were paid to the Company by its RENACIDIN supplier in connection with the supplier's curtailment of RENACIDIN production (see "Pharmaceuticals" above). The Company entered into an agreement with its RENACIDIN supplier whereby the supplier agreed to pay the Company $97,610 per month until either production resumes or the supply agreement ends on January 20, 2014, whichever comes first. Production is not expected to resume until the end of the third quarter of 2013. For more information see the Company's Annual report on Form 10-K for 2012.
The Company earns interest income from money market funds and bonds, and dividend income from both stock and bond mutual funds. In addition to Other Income increasing in the second quarter of 2013 as a result of the RENACIDIN settlement, the Company's investment income for the second quarter of 2013 also increased by $23,168 (55.5%) compared with the comparable quarter of 2012. The increase was mainly attributable to capital gains recognized on the sale of mutual funds. For the first half of 2013 investment income increased by $7,759 (7.0%) as compared with the first half of 2012.
Provision for Income Taxes
The provision for income taxes increased by $74,200 (13.0%) and $246,300 (21.2%) for the three and six months, respectively, ended June 30, 2013, when compared with the comparable periods in 2012. The increase for the second quarter of 2013 was mainly due to an increase in income before taxes of $223,656 (12.7%). The increase for the first half of 2013 was attributable to an increase in income before taxes of $731,775 (20.4%).
The Company's effective income tax rate remained approximately 33.0% for all periods presented.
LIQUIDITY AND CAPITAL RESOURCES
Working capital increased from $11,795,895 at December 31, 2012 to $12,359,730 at June 30, 2013, an increase of $563,835. The increase was primarily due to an increase in accounts receivable, marketable securities, and cash. The current ratio decreased from 15.25 to 1 at December 31, 2012 to 10.53 to 1 at June 30, 2013. The decrease in the current ratio was primarily due to the effect of an increase in accrued expenses.
During the first half of 2013 the average period of time that an account receivable was outstanding was approximately 29 days. The average period of time that an account receivable was outstanding during the first half of 2012 was approximately 44 days. This reduction in the average time that a receivable was outstanding was due to (a) the company’s largest marketing partner paying its invoices in a more timely fashion, and (b) a decrease in receivables related to RENACIDIN, which historically were outstanding longer than receivables for the Company’s other product lines.
Page 15 of 18
The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The only significant capital expenditures the Company anticipates it will incur for the remainder of 2013 is in connection with the change in the Company’s contract manufacturer for RENACIDIN. The Company has in place a commitment to spend approximately $167,000 for a mold and related production equipment needed to produce the product in a new plastic bottle (see Note 13 above). It also estimates that consulting and other costs related to preparing a new submission to the FDA to obtain approval of its new bottle and supplier will involve the payment of at least an additional $150,000. This does not include the costs involved in manufacturing three production batches that will probably be required as part of the FDA approval process but which the Company anticipates can later be sold. Please see the Company’s filing on Form 10-K for FY-2012 for further details on RENACIDIN.
The Company generated cash from operations of $3,614,283 and $2,787,745 for the first half of 2013 and 2012, respectively. The increase was primarily due to an increase in net income, as well as the receipt of settlement income that was earned in the prior year.
Cash used in investing activities for the first half of 2013 and 2012 was $1,098,785 and $112,101, respectively. This increase was primarily due to an increase in the purchases of marketable securities in the first six months of 2013 compared with the comparable period in 2012.
Cash used in financing activities was $2,160,326 and $1,930,504 for the first half of 2013 and 2012, respectively. This increase was mainly due to an increase in dividends paid per share from $0.42 per share in 2012 to $0.47 per share in 2013.
The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of other opportunities that are in the best interest of the Company and its shareholders, should they arise.
RECENT ACCOUNTING PRONOUNCEMENTS
See Note 4 to the Condensed Financial Statements for a description of recent accounting pronouncements, including the expected dates of adoption and the anticipated impact on the financial statements.
OFF-BALANCE-SHEET ARRANGEMENTS
The Company has no off-balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
The information to be reported under this item is not required of smaller reporting companies.
Page 16 of 18
The information to be reported under this item is not required of smaller reporting companies.
|
Item 4.
|
|
(a)
|
DISCLOSURE CONTROLS AND PROCEDURES
|
The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.
|
(b)
|
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
|
The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.
|
LEGAL PROCEEDINGS
|
NONE
|
RISK FACTORS
|
The information to be reported under this item is not required of smaller reporting companies.
Page 17 of 18
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
|
NONE
|
DEFAULTS UPON SENIOR SECURITIES
|
NONE
|
MINE SAFETY DISCLOSURES
|
NONE
|
OTHER INFORMATION
|
NONE
|
EXHIBITS
|
|
31.1
|
Certification of Kenneth H. Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
Certification of Robert S. Rubinger, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32
|
Certifications of the Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
UNITED-GUARDIAN, INC.
|
|||
|
(Registrant)
|
|||
|
By:
|
/S/ KENNETH H. GLOBUS
|
||
|
Kenneth H. Globus
|
|||
|
President
|
|||
|
By:
|
/S/ ROBERT S. RUBINGER
|
||
|
Robert S. Rubinger
|
|||
|
Chief Financial Officer
|
|||
|
Date: August 7, 2013
|
|||
Page 18 of 18